CN115867355A - 用于治疗系统性硬化病的抗s100a4抗体 - Google Patents

用于治疗系统性硬化病的抗s100a4抗体 Download PDF

Info

Publication number
CN115867355A
CN115867355A CN202180045596.5A CN202180045596A CN115867355A CN 115867355 A CN115867355 A CN 115867355A CN 202180045596 A CN202180045596 A CN 202180045596A CN 115867355 A CN115867355 A CN 115867355A
Authority
CN
China
Prior art keywords
antibody
seq
thr
gly
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180045596.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·克林格霍夫
J·海伦
R·I·侯赛因
J·H·W·迪斯特勒
M·托马西克
T·巴斯
D·麦卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alex Therapeutics Co ltd
Original Assignee
Alex Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alex Therapeutics Co ltd filed Critical Alex Therapeutics Co ltd
Publication of CN115867355A publication Critical patent/CN115867355A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180045596.5A 2020-06-30 2021-06-30 用于治疗系统性硬化病的抗s100a4抗体 Pending CN115867355A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20183251.6 2020-06-30
EP20183251 2020-06-30
US202163147485P 2021-02-09 2021-02-09
US63/147,485 2021-02-09
PCT/EP2021/068038 WO2022003042A1 (en) 2020-06-30 2021-06-30 Anti-s100a4 antibodies for the treatment of systemic sclerosis

Publications (1)

Publication Number Publication Date
CN115867355A true CN115867355A (zh) 2023-03-28

Family

ID=76601225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180045596.5A Pending CN115867355A (zh) 2020-06-30 2021-06-30 用于治疗系统性硬化病的抗s100a4抗体

Country Status (7)

Country Link
US (1) US20230220058A1 (https=)
EP (1) EP4171752A1 (https=)
JP (1) JP2023531230A (https=)
CN (1) CN115867355A (https=)
AU (1) AU2021301244A1 (https=)
CA (1) CA3183062A1 (https=)
WO (1) WO2022003042A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117686722A (zh) * 2023-12-20 2024-03-12 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250011405A1 (en) * 2021-11-19 2025-01-09 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
WO2025188905A1 (en) * 2024-03-08 2025-09-12 The Board Of Regents Of The University Of Texas System Anti-s100a antibodies and related compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201290B (zh) * 2010-06-14 2016-09-28 莱克拉生物医学股份公司 S100a4抗体及其治疗用途
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
GB201219487D0 (en) 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
CA3207703A1 (en) * 2021-02-09 2022-08-18 Jonas Hallen Anti-s100a4 humanized antibodies, uses and methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117686722A (zh) * 2023-12-20 2024-03-12 内蒙古元牛繁育科技有限公司 一种s100a4纳米抗体及其应用

Also Published As

Publication number Publication date
JP2023531230A (ja) 2023-07-21
AU2021301244A1 (en) 2023-03-02
WO2022003042A1 (en) 2022-01-06
CA3183062A1 (en) 2022-01-06
EP4171752A1 (en) 2023-05-03
US20230220058A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
AU2018233976B2 (en) Fc-optimized anti-CD25 for tumour specific cell depletion
KR102306366B1 (ko) Cd127에 대해 지시된 항체 및 폴리펩타이드
US20210145977A1 (en) Methods and pharmaceutical composition for the treatment of cancer
WO2020177733A1 (zh) 双功能融合蛋白及其医药用途
AU2018266784C1 (en) LRRC33 inhibitors and use thereof
KR101800467B1 (ko) 루푸스 치료 방법 및 조성물
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
KR101681331B1 (ko) 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제
JP2022512642A (ja) がんを治療するための抗ＭｅｒＴＫ抗体
CN115867355A (zh) 用于治疗系统性硬化病的抗s100a4抗体
US12304949B2 (en) Anti-S100A4 humanized antibodies, uses and methods
CN113271964A (zh) 化脓性汗腺炎治疗中使用的抗cd40抗体
KR20130100918A (ko) Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능
US20220331425A1 (en) Treatment of cancers with gm-csf antagonists
NL2021591B1 (en) MuSK activation
CN117355331A (zh) 抗Siglec组合物及其用途
US20240043562A1 (en) Musk activation
NL2021589B1 (en) MuSK inhibition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination